Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs)

 

 Buy Article Permissions and Reprints

Zusammenfassung

Einleitung In Deutschland sind mehr als 250 000 Patienten an einer chronischen Hepatitis C (CHC) erkrankt. Seit 2014 sind zahlreiche potente direkt antivirale Substanzen gegen HCV zugelassen worden. Ziel des Deutschen Hepatitis-C-Registers (DHC-R) ist es, die Epidemiologie und Versorgung von Patienten mit CHC abzubilden und die Effektivität und Sicherheit der neuen Behandlungsmöglichkeiten im Praxisalltag zu untersuchen.

Methoden Das DHC-R ist eine prospektive, multizentrische, nicht interventionelle Registerstudie. Bundesweit sind 327 Zentren für die Dokumentation freigeschaltet. Alle in Deutschland zugelassenen Medikamente wurden im DHC-R dokumentiert. Für die aktuelle Auswertung wurden 4 Phasen unterschieden: 2/2014 bis 12/2014, 1/2015 bis 12/2015, 1/2016 bis 7/2017 und 8/2017 bis 7/2018.

Ergebnisse Zwischen Februar 2014 und Juli 2018 wurden 12 170 Patienten in das Register eingeschlossen (61,3 % Männer), eine antivirale Therapie erhielten 11 268. Das Behandlungsalter sank von 52,3 (Phase 1) auf 49,3 Jahre (Phase 4), der Anteil der Behandelten mit einer Drogenanamnese nahm zu (von 26,9 auf 43,1 %). 2014 wurden viele Patienten mit Leberzirrhose (35,1 %) behandelt, deren Anteil im Verlauf deutlich abnahm (Phase 4: 16,5 %). Die HCV-Genotypenverteilung änderte sich im Zeitverlauf deutlich, zuletzt stieg der Anteil des HCV-Genotyps 3 (30 % in Phase 4). Die Ausheilungsrate (PP-Analyse) steigerte sich von 92,8 % im Jahre 2014 auf zuletzt 97,4 % bei sehr guter Verträglichkeit.

Zusammenfassung Das DHC-R beschreibt die Versorgungssituation der Patienten mit CHC in Deutschland, zeigt epidemiologische Tendenzen auf und belegt die ausgezeichneten Behandlungsmöglichkeiten.

Abstract

Background More than 250 000 patients suffer from chronic hepatitis C in Germany. Several potent, direct-acting antiviral drugs have been approved since 2014. The aim of the German Hepatitis C-Registry (DHC-R) is to describe the epidemiology and patient care of hepatitis C and to investigate the efficacy and safety of new treatment options in real-world settings.

Methods The DHC-R is a prospective multicenter non-interventional registry study that includes 327 centers throughout Germany. All approved treatment options have been documented. The current analysis differentiated 4 phases: 2/2014 – 12/2014, 1/2015 – 12/2015, 1/2016 – 7/2017 and 8/2017 – 7/2018.

Findings Between February 2014 and July 2018, 12 170 patients were included in the registry (61.3 % male), and antiviral treatment was initiated in 11 268. The mean age declined from 52.3 years (phase 1) to 49.3 years (phase 4), while the proportion of patients with previous or ongoing drug abuse increased (26.3 % to 43.1 %). In 2014, 35.1 % of treated patients had liver cirrhosis, which declined to 16.5 % in phase 4. The HCV genotype distribution showed marked fluctuations, with most recent increases in HCV genotype 3 (30 % in phase 4). Per-protocol sustained virological response rates increased from 92.8 % in 2014 to 94.4 % in 2017/18 with excellent tolerability.

Summary The DHC-R mirrors patient care of chronic hepatitis in the real-world setting in Germany and provides insights into epidemiology developments. It also confirms the high efficacy and safety of novel treatment options.

• Literatur

• 1 Polaris Observatory HCV. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161-176
  PubMedGoogle Scholar
• 2 Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 4: 401-412
  PubMedGoogle Scholar
• 3 Vermehren J, Park JS, Jacobson IM. et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018; 5: 1178-1187
  PubMedGoogle Scholar
• 4 Sarrazin C, Zimmermann T, Berg T. et al. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion“. Z Gastroenterol 2018; 56: 756-838
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Hüppe D, Zehnter E, Mauss S. et al. Epidemiologie der chronischen Hepatitis C in Deutschland – Eine Analyse von 10326 Hepatitis-C-Virus-Infizierten aus Schwerpunktpraxen und -ambulanzen. Z Gastroenterol 2008; 46: 34-44
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Mauss S, Böker K, Buggisch P. et al. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Z Gastroenterol 2015; 7: 644-654
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Wedemeyer H. Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study. Liv Int 2017; 37: 1468-1475
  CrossrefPubMedGoogle Scholar
• 8 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018 https://doi.org/10.1016/j.jhep.2018.03.026
  CrossrefPubMedGoogle Scholar
• 9 Höner zuSiederdissen C, Buggisch P, Böker KHW. et al. Treatment of Hepatitis C genotype 1 infection in Germany – effectiveness and safety of antiviral treatment in a real world setting. UEG Journal 2018; 6: 213-224
  PubMedGoogle Scholar
• 10 Tacke F, Günther R, Buggisch P. et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int 2017; 37: 205-211
  CrossrefPubMedGoogle Scholar
• 11 Cornberg M, Petersen J, Schober A. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. AP&T 2017; 45: 688-700
  PubMedGoogle Scholar
• 12 Welzel TM, Hinrichsen H, Sarrazin C. et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepatitis 2017; 24: 840-849
  CrossrefPubMedGoogle Scholar
• 13 Buggisch P, Vermehren J, Mauss S. et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hep 2018; 68: 663-671
  CrossrefPubMedGoogle Scholar
• 14 Bischoff J, Mauss S, Cordes D. et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Medicine 2018; 19: 299-307
  CrossrefPubMedGoogle Scholar
• 15 Bischoff J, Mauss S, Cordes D. et al. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: Insights from the German Hepatitis C-Registry. HIV Clinical Trials 2018; zur Veröffentlichung angenommen
  PubMedGoogle Scholar
• 16 Christensen S, Buggisch P, Mauss S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction 2018; 113: 868-882
  CrossrefPubMedGoogle Scholar
• 17 Herzer K, Gerken G, Kroy D. et al. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of Hepatology 2018; 69: 982-984
  CrossrefPubMedGoogle Scholar
• 18 Dultz G, Müller T, Petersen J. et al. Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients: Results from the German Hepatitis C-Registry. Drugs & Aging 2018; 35: 843-857
  CrossrefPubMedGoogle Scholar
• 19 Maasoumy B, Buggisch P, Mauss S. et al. Frequency and predictive value of detectable and quantifiable HCV RNA at the end of antiviral therapy in a large real-world cohort. Liver Int 2018; 38: 1906-1910
  CrossrefPubMedGoogle Scholar
• 20 Krüger K, Krauth C, Rossol S. et al. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2018; DOI: 10.1097/MEG.0000000000001283.
  CrossrefPubMedGoogle Scholar
• 21 Knop V, Hofmann WP, Buggisch P. et al. Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment. J Viral Hepatitis 2018; DOI: 10.1111/jvh.13021.
  CrossrefPubMedGoogle Scholar
• 22 Vermehren J, Stoehr A, Schulze zurWiesch J. et al. Re-Therapie von DAA-Versagern mit Sofosbuvir/Velpatasvir/Voxilaprevir – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R). Z Gastroenterol 2018; 56: e290
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Hüppe D, Buggisch P, Christensen C. et al. Patienten mit chronischer Hepatitis C vor Einführung der Interferon-freien Therapie in Deutschland. Z Gastroenterol 2016; 54: 740-747
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Deterding K, Mauss S, Pathil A. et al. Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R). J Hepatol 2017; 66: S55
  PubMedGoogle Scholar
• 25 Zimmermann R, Kollan C, Ingiliz P. et al. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015. J Hepatol 2017; 67: 15-22
  CrossrefPubMedGoogle Scholar
• 26 Hajarizadeh B, Cunningham EB, Reid H. et al. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018; 3: P754-P767
  PubMedGoogle Scholar
• 27 Christensen S, Buggisch P, Mauss S. et al. Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R). J Hepatol 2018; 68: S21-S22
  CrossrefPubMedGoogle Scholar